ClinicalTrials.gg
RecruitingNCT07869537Updated Oct 9, 2026

The Safety of Simplified Tranexamic Acid Regimen

A Phase 4 interventional study of Tranexamic Acid (TXA) in Trauma Coagulopathy and Hemorrhage, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Treatment

Updated Oct 9, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 133 studies testing Tranexamic Acid in Hemorrhage — 21 open to participants now, 24 under way, 11 of them phase 3. Tranexamic Acid · Hemorrhage.

Planned enrollment
98th of 132
60 · median 102
Started
2026
with 5 others
Phase 4
51 of 133
8 open now
Primary completion
2027-03
later than 13 of 23 live
Registered
133rd of 133
by date

Among the 133 studies testing Tranexamic Acid in Hemorrhage, this one is the 98th largest by planned enrollment of the 132 interventional ones that give a count, is one of 6 that started in 2026, is one of 51 in phase 4, reaches primary completion later than 13 of the 23 other live ones, and was the 133rd registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

21 of the 133 studies testing Tranexamic Acid in Hemorrhage are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies testing Tranexamic Acid in Hemorrhage, or all of them as a file.
02

Study summary

Trauma causes at least 5.8 million deaths worldwide annually, accounting for 1 in 10 of all global deaths. Uncontrolled bleeding within 24 hours after trauma is the leading cause of death in trauma patients, and about one-third of patients present with trauma-induced coagulopathy on admission. Fatal severe traumatic hemorrhage is the most common preventable factor contributing to death.

Tranexamic acid (TXA), a synthetic lysine derivative, competitively inhibits plasminogen activation, preventing fibrin clot breakdown and thereby enhancing hemostasis and reducing blood loss. Randomized controlled trials such as CRASH-2 have confirmed that TXA significantly reduces mortality in patients with severe traumatic bleeding. TXA has therefore become a cornerstone of traumatic hemorrhage treatment, with current international guidelines recommending 1 g intravenous bolus (over >10 minutes) plus 1 g intravenous maintenance infusion (over 8 hours).

However, severe traumatic hemorrhage is typically managed in high-pressure, chaotic battlefield or emergency settings, where this complex, time-sensitive, multi-step divided regimen is difficult to fully execute in real-world practice. The omission rate of the second maintenance infusion is particularly high, reaching up to 67% during prehospital-to-hospital handover. Rowell et al. showed that even with a strict research protocol, completion of the planned 8-hour in-hospital maintenance infusion was only about 70%. Previous pharmacokinetic studies found that without the second maintenance dose, 21% of patients receiving an initial 1 g dose had already failed to achieve effective plasma concentrations at hospital admission (approximately 1.5 hours post-dose). Thus, the inherent difficulty of fully executing the divided regimen may prevent patients from receiving the full benefits of TXA.

To address this, a simplified regimen of a single 2 g loading dose without maintenance infusion has been recommended in recent expert consensus statements, especially for prehospital or battlefield settings. However, these recommendations were mainly based on the 2020 Rowell et al. randomized controlled study, whose exploratory analysis suggested potential mortality reduction with the simplified regimen. That study enrolled patients with traumatic brain injury and had limited statistical power, so evidence on the efficacy and safety of the simplified regimen in patients with severe traumatic hemorrhage remains lacking. Based on the pharmacokinetic study by Grassin-Delyle et al., a single 2 g loading dose is hypothesized to maintain effective concentrations during the peak fibrinolytic period (within 3 hours post-injury), while the transient peak plasma concentration remains well below the toxicity threshold of 500 μg/mL. We therefore hypothesize that, in patients with severe traumatic hemorrhage, the simplified TXA regimen is non-inferior to the divided regimen in efficacy, including bleeding control.

However, the primary limitation of a large randomized controlled trial to verify this hypothesis is that safety concerns regarding the simplified regimen due to higher transient plasma concentrations compared with the divided regimen have not been clearly resolved. Previous systematic reviews concluded that safety events such as thrombosis and seizures are dose-dependent, and that a total daily dose not exceeding 2 g is safe. Previous pharmacokinetic studies also suggest that the transient peak concentration of the simplified regimen should be well below the toxicity threshold. Although expert consensus has recommended the simplified regimen, suggesting it can be considered safe, studies directly comparing the two regimens are lacking, particularly regarding whether the simplified regimen increases safety risks when the total dose is identical. Before conducting a larger, more definitive efficacy trial, it is also important to evaluate recruitment rates, protocol adherence, accurate sample size estimation, and other potential barriers. For these reasons, we designed this pilot study, primarily to evaluate the safety of the simplified TXA regimen compared with the divided regimen in patients with traumatic hemorrhagic shock, and the feasibility of a subsequent randomized controlled trial.

03

Conditions studied

  • Trauma Coagulopathy
  • Hemorrhage

Keywords

  • trauma
  • hemorrhage
  • coagulopathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Trauma patients
  • Significant hemorrhage (systolic blood pressure \<90 mm Hg or heart rate >110 beats per min, or both) or clinical assessment of risk of massive transfusion (massive transfusion was defined as administration of at least 3 PRBC within the hour of admission or at least 10 PRBC within the first 24 hours)
  • who were within 3 h of injury
  • To obtain (or comply with the requirements for emergency exemptions agree)

Exclusion criteria

Exclusion Criteria:

  • Known to be allergic to TXA
  • Pregnancy
  • Traumatic cardiac arrest occurring prior to or at the time of admission, or patients with a high risk of death within 3 hours of admission
  • History of thrombotic disease (such as DVT and PE, MI, stroke)
  • History of epilepsy
  • Injury time is unknown or > 3 hours
  • have received TXA before admission.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Simplified Tranexamic Acid Regimen

    Tranexamic Acid was administered intravenously within 3 hours after injury, with a loading dose of 2 g, and the infusion was completed after more than 20 minutes without a second dose.

    Drug: Tranexamic Acid (TXA)

  • Active comparator
    Divided-Dose Tranexamic Acid Regimen

    Tranexamic Acid is administered intravenously within 3 hours after injury, with a loading dose of 1 g, and the infusion is completed after more than 10 minutes. The second dose of 1 g is maintained for 8 hours.

    Drug: Tranexamic Acid (TXA)

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of thrombotic events

    Including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, cerebral infarction and other thrombotic events

    Time frame: in hospital

Secondary outcomes

  1. the incidence of deep venous thrombosis

    Time frame: 24 hour

  2. the incidence of deep venous thrombosis

    Time frame: in hospital

  3. the incidence of pulmonary embolism

    Time frame: in hospital

  4. the incidence of myocardial infarction

    Time frame: in hospital

  5. the incidence of cerebrovascular embolism

    Time frame: in hospital

  6. the incidence of other thrombotic events

    Time frame: in hospital

  7. the incidence of seizure or seizure-like activity

    Time frame: in hospital

  8. The incidence of hypotension

    Time frame: Within 30min after TXA bolus

  9. The duration of hypotension after TXA bolus

    Time frame: in hospital

  10. The incidence of acute kidney injury

    Time frame: in hospital

  11. Percentage of clot lysed at 30 min following maximum amplitude

    CL30 \< 0.8% (fibrinolysis shutdown), 0.8≤CL30≤3% (normal ), and CL30 \> 3% (hyperfibrinolysis)

    Time frame: 3 hour after TXA bolus

  12. Percentage of clot lysed at 30 min following maximum amplitude

    CL30 \< 0.8% (fibrinolysis shutdown), 0.8≤CL30≤3% (normal ), and CL30 \> 3% (hyperfibrinolysis)

    Time frame: 24 hour

  13. mortality

    Time frame: 24 hour

  14. mortality of bleeding

    Time frame: 24 hour

  15. mortality

    Time frame: Day 28

  16. mortality of bleeding

    Time frame: Day 28

  17. Total blood product consumption

    Time frame: 24 hour

  18. Red blood cell consumption

    Time frame: 24 hour

  19. Fresh frozen plasma consumption

    Time frame: 24 hour

  20. Platelet concentrate consumption

    Time frame: 24 hour

  21. Hospital-free days

    Time frame: Day 28

  22. Ventilator-free days

    Time frame: Day 28

  23. ICU-free days

    Time frame: Day 28

07

Study locations

3 of 3 sites recruiting
  • the Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
  • Jiaxing First Hospital
    Jiaxin, Zhejiang, China
    Recruiting
  • Third Affiliated Hospital, Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 92 non-industry phase 4 interventional studies under Hemorrhage, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 5 months is below that.

Counting every sponsor, half of 96 studies reached it within 28 months; a quarter within 18 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 9, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07869537
Collaborators
Affiliated Hospital of Jiaxing University, The Third Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Quzhou, Jinhua Central Hospital
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

yongan xu
Contact
xuyongan2000@zju.edu.cn
0571-87998893
yongan xu, PhD
study chair · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion